Category Archives: CNS drugs

Quetiapine extended release tablets (Seroquel XR): efficacy, tolerability and adherence.

Information about quetiapine extended release tablets, from the National Prescribing Service RADAR “There is no evidence that extended-release tablets improve efficacy, tolerability or adherence Once-daily dosing with quetiapine extended-release tablets is equivalent to twice-daily dosing with quetiapine immediate-release tablets, e.g. quetiapine extended release 600 mg once daily is equivalent to quetiapine immediate release 300 mgContinue Reading

Antiepileptic drugs (AEDs): FDA requires warnings about suicidal thoughts and behaviors (suicidality)

The FDA will require manufacturers of antiepileptic drugs (AEDs) to inclued a warning about the increased risk of suicidal thoughts and behaviours when using these drugs. This is a transcript of the original press release dated Dec. 16, 2008: FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications The U.S. FoodContinue Reading

Zolpidem, zoplicone and zaleplon (z-drugs) side effects profile: Australian Prescriber press release

Hypnotic hazards and effects of z-drugs immeasurable “It is difficult to know the extent of use and adverse effects of zolpidem and other z-drugs (zopiclone and zaleplon) because they have never been listed on the Australian Pharmaceutical Benefits Scheme, senior Sleep Disorders Physician Dr Les Olson writes in the latest edition of Australian Prescriber.Continue Reading

Phenytoin and fosphenytoin linked to Stevens Johnson syndrome and toxic epidermal necrolysis

From the FDA website: FDA is investigating new preliminary data regarding a potential increased risk of serious skin reactions including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from phenytoin therapy in Asian patients positive for a particular human leukocyte antigen (HLA) allele, HLA-B*1502. This allele occurs almost exclusively in patients with ancestry acrossContinue Reading

Risk of death in patients with dementia that use typical antipsychotics: EMEA’s press release

Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia The European Medicines Agency (EMEA) has completed a review of the evidence available on the safety of conventional antipsychotic medicines in elderly patients with dementia. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that thereContinue Reading

SSRIs, SNRIs and SSNRIs: clinical guideline by the ACP

The American College of Physicians has issued a Clinical Practice Guideline about the use of Second-Generation Antidepressants in the treatment of Depressive Disorders. The recommendations that arise from it are the following: Recommendation 1: The American College of Physicians recommends that when clinicians choose pharmacologic therapy to treat patients with acute major depression, they selectContinue Reading

Rufinamide approved as adjunctive for Lennox Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome. “This approval offers another treatment option for patients who suffer from these debilitating, severe seizures,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’sContinue Reading

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos